Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Javier Garcia-Corbacho"'
Autor:
Seock-Ah Im, Kevin Norwood, Donna M. Graham, Hyun Cheol Chung, Esma Saada-Bouzid, Alan D. Smith, Juanita Lopez, Javier Garcia-Corbacho, Carlos Gomez-Roca, Eduardo Castanon, Eduardo Yanez, Federico Longo Muñoz, Corina E. Dutcus, Razi Ghori
Publikováno v:
Cancer Research. 81:PS12-07
Background: Triple-negative breast cancer (TNBC) is associated with poor survival outcomes and treatment options are limited. These tumors lack therapeutic targets and become rapidly resistant to chemotherapy. The anti–PD-1 antibody pembrolizumab s
Autor:
Andy Sykes, Christopher J. Morrow, Richard D. Baird, Teresa Klinowska, Rhiannon Maudsley, Marta Capelán Rodríguez, Manuel Ruiz-Borrego, Tim Brier, Bistra Kirova, Justin P.O. Lindemann, Nitharsan Sathiyayogan, Christina Hernando, Julia Lai-Kwon, Javier Garcia-Corbacho, Judy S. Wang, Begoña Bermejo de las Heras, Steven Fox, Mafalda Oliveira, Chris Leach, Eva Maria Ciruelos Gil, Anne C Armstrong, Richard Mather, Erika Hamilton, Manish R. Patel, Jason Incorvati, Udai Banerji, Valentina Boni, Chris Twelves, Ivan Victoria Ruiz, Bruno de Paula, Alejandro González, Li Zhang, Anosheh Afghani, Peter Kabos, Christos Vaklavas, Adam L. Cohen
Publikováno v:
Cancer Research. 81:PS11-05
Background: AZD9833 is an oral selective estrogen receptor (ER) antagonist and degrader (SERD) in Phase 2 clinical development for the treatment of ER+ HER2− breast cancer. Here we report data from Parts C and D of the ongoing Phase 1 study (SERENA
Autor:
R. Blanco, Judith Dalmau, Javier Martinez-Picado, M. González Cao, Teresa Moran, M. Provencio Pulla, J. De Castro Carpeno, Ana Drozdowskyj, R. Rosell Costa, R. Bernabé, Bonaventura Clotet, Julia G. Prado, O.J. Juan Vidal, Julià Blanco, Javier Garcia-Corbacho, M.A. Molina-Vila, B. Massuti Sureda, Andreas Meyerhans
Publikováno v:
Annals of Oncology. 31:S825
Autor:
Javier Garcia-Corbacho, R. Bernabé, Christian Brander, Niki Karachaliou, Rafael Rosell, Andreas Meyerhans, Oscar Juan, Judith Dalmau, Bonaventura Clotet, Julia Garcia-Prado, Mariano Provencio, Javier Martinez-Picado, Javier de Castro, Bartomeu Massuti, Maria Gonzalez-Cao, Julià Blanco, Miguel Angel Molina Vila, Jorge Carrillo, Remei Blanco, Teresa Moran
Publikováno v:
Journal of Clinical Oncology. 37:2501-2501
2501 Background: Durvalumab (MEDI4736), a programmed cell death-ligand 1 (PD-L1) blocking antibody, is currently approved for treatment of several cancer types. As HIV-1-infected (HIV+) patients have been excluded from cancer clinical trials, there a